Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Shell Asset Management Co. increased its stake in Alnylam Pharmaceuticals by 28.3%, acquiring an additional 1,602 shares, bringing its total to 7,257 shares valued at approximately $2.37 million.
• Several institutional investors have also adjusted their positions, with Vanguard Group increasing its stake to over 13 million shares, valued at $3.53 billion.
• Wall Street analysts are optimistic about Alnylam Pharmaceuticals, with 24 analysts rating it as a buy, while the Goldman Sachs Group raised its target price to $566.00.

Shell Asset Management Co. grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 28.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,257 shares of the biopharmaceutical company's stock after purchasing an additional 1,602 shares during the period. Shell Asset Management Co.'s holdings in Alnylam Pharmaceuticals were worth $2,366,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ALNY. Vanguard Group Inc. boosted its position in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock worth $3,525,544,000 after purchasing an additional 323,206 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $69,292,000. Adage Capital Partners GP L.L.C. boosted its position in shares of Alnylam Pharmaceuticals by 203.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 282,184 shares of the biopharmaceutical company's stock worth $76,195,000 after purchasing an additional 189,128 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after purchasing an additional 185,783 shares in the last quarter. Finally, SCS Capital Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth about $46,194,000. Institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ALNY shares. The Goldman Sachs Group upped their target price on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a "buy" rating in a report on Tuesday, September 16th. UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Raymond James Financial started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 target price on the stock. Citigroup upped their target price on shares of Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Finally, Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, October 4th. Twenty-four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $448.04.

Insider Activity

In other news, Director Dennis A. Ausiello sold 31,448 shares of the stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director directly owned 911 shares of the company's stock, valued at $397,724.38. This represents a 97.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the completion of the transaction, the director directly owned 16,804 shares of the company's stock, valued at approximately $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Down 1.9%

Alnylam Pharmaceuticals stock opened at $450.68 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The firm has a 50 day moving average price of $448.91 and a 200-day moving average price of $342.70. The company has a market capitalization of $59.08 billion, a P/E ratio of -182.46 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same period in the prior year, the firm earned ($0.13) EPS. The company's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.